


Claims

1. A compound of formula (I):



wherein A⁻ represents the benzenesulphonate (besylate) anion;.

R represents H or C₁₋₆ alkyl; and

n is a number from 0.8 to 2.2.

10

2. A compound of formula (I) according to claim 1 wherein R represents H.

3. A compound of formula (I) according to claim 1 or claim 2 wherein n represents a number between 1.1 and 2.1.

15


4. A compound of formula (I) according to any one of claims 1 to 3 wherein n is about 2.

5. A compound according to any one of claims 1 to 4 which is 4-((((((2S)-4-

20 (3,4-dichlorobenzyl)morpholin-2-yl)methylamino)carbonyl]amino} methyl)benzamide benzenesulfonate dihydrate.


6. A process for the preparation of a compound of formula (I) as defined in claim 1, which process comprises the reaction of a compound of formula (IA);

25




with a source of the besylate anion and a suitable C₁₋₆alkanol and water.

7. A compound of formula (I) as defined in claim 1 for use as a therapeutic agent, particularly in the treatment of patients with inflammatory conditions, eg. asthma or rhinitis.
8. Use of a compound of formula (I) as defined in claim 1 for the manufacture of a medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.
9. A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition eg. asthma or rhinitis, which method comprises administering to said human or animal subject an effective amount of a compound of formula (I) as defined in claim 1.
10. A pharmaceutical composition, comprising a compound of formula (I) as defined in claim 1 optionally with one or more physiologically acceptable diluents or carriers.
11. A compound of formula (IIA)



12. A compound of formula (IIBR)



13. A compound of formula (IIB)

